Immatics Q3 Sales $7.40M Down From $9.10M YoY
Immatics (NASDAQ:IMTX) reported $7.40 million in sales this quarter. This is a 18.68 percent decrease over sales of $9.10 million the same period last year.
Immatics Reports Clinical Responses Across Multiple Solid Tumor Types In Ongoing ACTengine IMA203 Phase 1a Trial Targeting PRAME
Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billion transduced cells
Objective responses (RECIST 1.1) observed in 8/16 patients (50%) across
Immatics To Present Update On Lead ACTengine Program IMA203 Targeting PRAME At The Society For Immunotherapy Of Cancer’s 36th Annual Meeting
Immatics N.V. (NASDAQ:IMTX, &ldquo, Immatics&rdquo, )), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the company
Immatics: Q2 Earnings Insights
Shares of Immatics (NASDAQ:IMTX) were unchanged after the company reported Q2 results.
Quarterly Results
Earnings per share fell 21.62% year over year to ($0.45), which missed the estimate of ($0.40).
Immatics Q2 Sales $6.20M Down From $8.20M YoY
Immatics (NASDAQ:IMTX) reported $6.20 million in sales this quarter. This is a 24.39 percent decrease over sales of $8.20 million the same period last year.
SVB Leerink Maintains Outperform on Immatics, Raises Price Target to $27
SVB Leerink analyst Jonathan Chang maintains Immatics (NASDAQ:IMTX) with a Outperform and raises the price target from $26 to $27.
BioCopy, Immatics Team Up For Characterization Of TCR-Peptide-HLA Interactions
Switzerland-based BioCopy AG has collaborated with Immatics N.V. (NASDAQ:IMTX) to characterize T cell receptors (TCRs). T cell receptors and their interactions with peptide-HLA…
14 Biotech Stocks To Watch Over The Next 6 Months
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks.
Immatics Granted U.S. Patent Titled ‘Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6664&f=G&l=50&d=PTXT&p=134&S1=20210615&OS=20210615&RS=20210615